reports
PennantPark Investment Corporation Announces Financial Results for the...
PennantPark Investment Corporation Announces Financial Results for the First Quarter Ended December 31, 2025 and Updates Dividend Strategy Going Forward MIAMI, Feb. 09, 2026 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (NYSE: PNNT) (the "Company") announced today financial results for the first quarter ended December 31, 2025. HIGHLIGHTS Quarter ended December 31, 2025 (unaudited)($ in millions, except per share amounts) Assets and Liabilities: Investment portfolio (1)$1,218.5 Net assets$457.2 Net asset value per share$7.00 Quarterly change in net asset value per share ...
- Jonathan Moreland
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
TCBI TEXAS CAPITAL BANCSHARES INC.
SXI STANDEX INTERNATIONAL CORPORATION
PAYX PAYCHEX INC.
NBTB NBT BANCORP INC.
MNRO MONRO INC
LXRX LEXICON PHARMACEUTICALS INC.
LMAT LEMAITRE VASCULAR INC.
HUN HUNTSMAN CORPORATION
GME GAMESTOP CORP. CLASS A
FFIN FIRST FINANCIAL BANKSHARES INC
CR CRANE CO.
GAM GENERAL AMERICAN INVESTORS CO. INC.
ENPH ENPHASE ENERGY INC.
PCF PUTNAM HIGH INCOME SECURITIES FUND
AGYS AGILYSYS INC.
TYIA JOHNSON CONTROLS INTERNATIONAL PLC
LW LAMB WESTON HOLDINGS INC.
HWKN HAWKINS INC.
WDFC WD-40 COMPANY
HYT BLACKROCK CORPORATE HIGH YIELD FUND VI
CVCO CAVCO INDUSTRIES INC.
CRVS CORVUS PHARMACEUTICALS
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
ABT ABBOTT LABORATORIES
MVBF MVB FINANCIAL CORP
THM INTERNATIONAL TOWER HILL MINES LTD
NWFL NORWOOD FINANCIAL CORP.
ZIVO ZIVO BIOSCIENCE
SONO INC.
ANIX SONOS
ETON ANIXA BIOSCIENCES
AMTB ETON PHARMACEUTICALS
JYNT AMERANT BANCORP (A)
ALLY THE JOINT
CMTV GMAC LLC
ALXO COMMUNITY BANCORP INC. VT
AZYO ALX ONCOLOGY HOLDINGS
LUMN AZIYO BIOLOGICS
BST LUMEN TECHNOLOGIES INC.
LSF BLACKROCK SCIENCE AND TECHNOLOGY TRUST
VANI LAIRD SUPERFOOD INC
BOF VIVANI MEDICAL INC
WS WI BRANCHOUT FOOD INC.
MXF WORTHINGTON STEEL
GDV THE MEXICO FUND
PMN INC.
IP THE GABELLI DIVIDEND & INCOME TRUST
CVM PROMIS NEUROSCIENCES INC.
FEAM INTER PHARMA PUBLIC COMPANY LIMITED
BDSX CEL-SCI CORPORATION
MIGI 5E ADVANCED MATERIALS INC.
BIODESIX INC
MAWSON INFRASTRUCTURE GROUP INC
- Jonathan Moreland
MNRO MONRO INC
HUN HUNTSMAN CORPORATION
ASA ASA
ENPH ENPHASE ENERGY INC.
TYIA JOHNSON CONTROLS INTERNATIONAL PLC
HYT BLACKROCK CORPORATE HIGH YIELD FUND VI
CVCO CAVCO INDUSTRIES INC.
ETON ETON PHARMACEUTICALS
LUMN LUMEN TECHNOLOGIES INC.
ZIP ZIPRECRUITER
TMC INC.
TBBK TMC THE METALS CO INC
LSF THE BANCORP
PMN INC.
GF LAIRD SUPERFOOD INC
PROMIS NEUROSCIENCES INC.
THE NEW GERMANY FUND
INC.
PennantPark Investment Corporation Announces Monthly Distribution of $...
PennantPark Investment Corporation Announces Monthly Distribution of $0.08 per Share MIAMI, Feb. 03, 2026 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (the "Company") (NYSE: PNNT) declares its monthly distribution for February 2026 of $0.08 per share, payable on March 2, 2026 to stockholders of record as of February 17, 2026. The distribution is expected to be paid from taxable net investment income. The final specific tax characteristics of the distribution will be reported to stockholders on Form 1099 after the end of the calendar year and in the Company's periodic report file...
RBB Bancorp Reports Fourth Quarter and Fiscal Year 2025 Earnings and D...
RBB Bancorp Reports Fourth Quarter and Fiscal Year 2025 Earnings and Declares Quarterly Cash Dividend of $0.16 Per Common Share LOS ANGELES, Jan. 26, 2026 (GLOBE NEWSWIRE) -- RBB Bancorp (NASDAQ:RBB) and its subsidiaries, Royal Business Bank (the “Bank”) and RBB Asset Management Company (“RAM”), collectively referred to herein as the “Company,” announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Highlights Net income totaled $10.2 million, or $0.59 diluted earnings per shareReturn on average assets of 0.96%, compared to 0.97% for the ...
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipate...
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM Expects to Report One-Year Cohort 1 Data and Early Cohort 2 Data from RIDGE™-1 Study of TN-401 for PKP2-Associated ARVC in First Half of 2026 Plans to Pursue Alignment on Regulatory Pathways for Lead Gene Therapy Programs in 2026 Raised $60 Million in 4Q25 to Support Runway Through mid-2027 SOUTH SAN FRANCISCO, Calif., J...
RBB Bancorp to Report Fourth Quarter and Fiscal Year 2025 Financial Re...
RBB Bancorp to Report Fourth Quarter and Fiscal Year 2025 Financial Results LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- RBB Bancorp (NASDAQ: ) and its subsidiaries, Royal Business Bank (the "Bank") and RBB Asset Management Company ("RAM"), collectively referred to herein as the "Company", today announced that it will release financial results for its fourth quarter and year ended December 31, 2025 after the markets close on Monday, January 26, 2026. Management will hold a conference call at 11:00 a.m. Pacific Time/2:00 p.m. Eastern Time on Tuesday, January 27, 2026, to discuss the Com...
PennantPark Investment Corporation Schedules Earnings Release of First...
PennantPark Investment Corporation Schedules Earnings Release of First Fiscal Quarter 2026 Results MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (the "Company") (NYSE: PNNT) announced that it will report results for the first fiscal quarter ended December 31, 2025 on Monday, February 9, 2026 after the close of the financial markets. The Company will also host a conference call at 12:00 p.m. (Eastern Time) on Tuesday, February 10, 2026 to discuss its financial results. All interested parties are welcome to participate. You can access the conference call by di...
PennantPark Investment Corporation Announces Monthly Distribution of $...
PennantPark Investment Corporation Announces Monthly Distribution of $0.08 per Share MIAMI, Jan. 05, 2026 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (the "Company") (NYSE: PNNT) declares its monthly distribution for January 2026 of $0.08 per share, payable on February 2, 2026 to stockholders of record as of January 16, 2026. The distribution is expected to be paid from taxable net investment income. The final specific tax characteristics of the distribution will be reported to stockholders on Form 1099 after the end of the calendar year and in the Company's periodic report fil...
PennantPark Investment Corporation Exits Significant Equity Investment...
PennantPark Investment Corporation Exits Significant Equity Investment and Upsizes Credit Facility MIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (NYSE: PNNT) (the "Company") announced that it has sold its equity investment in JF Intermediate, LLC ("JF") for $67.5 million, resulting in a realized gain of $63.1 million. This amount approximates the fair value of the investment as of September 30, 2025. JF represented 23% of the equity investment portfolio of the Company at fair value on that date, excluding its equity investment in PennantPark Senior Loan Fund ...
Tenaya Therapeutics Announces Pricing of Public Offering
Tenaya Therapeutics Announces Pricing of Public Offering SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 50,000,000 total units for gross proceeds of $60 million prior to deducting underwriting discounts and commissions and offering expenses. Tenaya intends to use the net proceeds from the offerin...
Tenaya Therapeutics Announces Proposed Public Offering
Tenaya Therapeutics Announces Proposed Public Offering SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and warrants to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of pre-funded warrants to purchase shares o...
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical...
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy MyPEAK-1 Protocol Amendments Agreed Upon with FDA; Tenaya Implementing Changes with Sites SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced it has received official notification from the U.S. Food and Drug Admin...
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RID...
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with More Than Six Months of Follow-Up Tenaya Management to Host a Webcast Conference Call Thursday, December 11 at 5:00 pm ET to Review Preliminary Results SOUTH SAN FRANCISCO, Calif., Dec. 11, 20...
PennantPark Investment Corporation Announces Monthly Distribution of $...
PennantPark Investment Corporation Announces Monthly Distribution of $0.08 per Share MIAMI, Dec. 02, 2025 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (the "Company") (NYSE: PNNT) declares its monthly distribution for December 2025 of $0.08 per share, payable on January 2, 2026 to stockholders of record as of December 15, 2025. The distribution is expected to be paid from taxable net investment income. The final specific tax characteristics of the distribution will be reported to stockholders on Form 1099 after the end of the calendar year and in the Company's periodic report fi...
PennantPark Investment Corporation Announces Financial Results for the...
PennantPark Investment Corporation Announces Financial Results for the Fourth Quarter and Fiscal Year Ended September 30, 2025 MIAMI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- PennantPark Investment Corporation (NYSE: PNNT) (the "Company") announced today financial results for the fourth quarter and fiscal year ended September 30, 2025. HIGHLIGHTS Year ended September 30, 2025($ in millions, except per share amounts) Assets and Liabilities: Investment portfolio (1) $1,287.3 Net assets $464.0 Net asset value per share $7.11 Quarterly change in net asset...
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and P...
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201 Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Transduction and MyBP-C Protein Expression Completed Dosing in Cohort 2 of RIDGE™-1 Trial of TN-401 for PKP2-associated ARVC; Cohort 1 Data On Track for Fourth Quarter Company Presentation Tenaya Management to Review New MyPEAK-1 ...
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPE...
Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research TN-201 Has Been Generally Well Tolerated at Both Doses Longer-term Follow Up of Cohort 1 Patients Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy Initial Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Trans...
- David Barden
Autumn for Broadband 3Q25 – FWA ascendant, Cable struggling
We share here, in our latest Autumn for Broadband report, a quick update on broadband industry trends based on reported company results so far. Industry net adds have improved substantially from a year ago but remain below last year’s when adjusted for ACP impact. Net adds for the quarter were higher than the pre-pandemic norm but trailing twelve-month net adds remain below pre-pandemic levels. We take a deep-dive into FWA’s continued strong momentum by carrier.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.